E-LIB Suche - Ergebnisse für: Andorsky, D. J.

1

P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (..:

Lansigan, F. ; Andorsky, D. J. ; Coleman, M....
HemaSphere. 6 (2022) - p. 1043-1044 , 2022

Link: https://doi.org/10.1097/..

2

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REV..:

Eyre, T. A. ; Wang, M. L. ; Shah, N. N....
HemaSphere. 6 (2022) - p. 991-992 , 2022

Link: https://doi.org/10.1097/..

3

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUD..:

Eyre, T. A. ; Shah, N. N. ; Le Gouill, S....
HemaSphere. 6 (2022) - p. 990-991 , 2022

Link: https://doi.org/10.1097/..

4

INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAP..:

. Lansigan, F ; . Parameswaran, V ; . Yacoub, A...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

5

INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAP..:

Sharman, J. P. ; Melear, J. M. ; Yacoub, A....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

6

INTERIM ANALYSIS OF MAGNIFY PHASE IIIB: INDUCTION R2 FOLLOW..:

Andorsky, D.J. ; Coleman, M. ; Yacoub, A....
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 222 , 2020

Link: https://doi.org/10.1016/..

7

Antibody–drug conjugates for previously treated aggressive ..:

Burke, J. M. ; Morschhauser, F. ; Andorsky, D...
Expert Review of Clinical Pharmacology. 13 (2020) 10 - p. 1073-1083 , 2020

Link: https://doi.org/10.1080/..

8

MAGNIFY PHASE IIIB INTERIM ANALYSIS: FIRST REPORT OF INDUCT..:

Sharman, J. ; Coleman, M. ; Yacoub, A....
Hematological Oncology. 37 (2019) S2 - p. 241-242 , 2019

Link: https://doi.org/10.1002/..

9

INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R..:

Sharman, J. ; Coleman, M. ; Yacoub, A....
Hematological Oncology. 37 (2019) S2 - p. 115-116 , 2019

Link: https://doi.org/10.1002/..

10

PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY..:

Coleman, M. ; Andorsky, D.J. ; Yacoub, A....
Hematological Oncology. 35 (2017) S2 - p. 148-148 , 2017

Link: https://doi.org/10.1002/..

11

Male involvement in cardiovascular preventive healthcare in..:

GOLDHABERFIEBERT, J ; GOLDHABERFIEBERT, S ; ANDORSKY, D
Preventive Medicine. 40 (2005) 6 - p. 690-695 , 2005

Link: https://doi.org/10.1016/..

12

Exploring treatment decision-making in chronic myeloid leuk..:

Andorsky, David ; Kota, Vamsi ; Sweet, Kendra
Frontiers in Oncology. 14 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

13

POSTER: CML-590 ASC4START: A Phase 3b, Open-Label, Randomiz..:

Strickland, Stephen ; Andorsky, David ; Brümmendorf, Tim...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S178 , 2023

Link: https://doi.org/10.1016/..

14

CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study..:

Strickland, Stephen ; Andorsky, David ; Brümmendorf, Tim...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S349-S350 , 2023

Link: https://doi.org/10.1016/..

15

MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Stu..:

Ito, Rodrigo ; Eyre, Toby A. ; Shah, Nirav N....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S395-S396 , 2022

Link: https://doi.org/10.1016/..